ATx201

Phase II - Exploratory (40 Patients)

  • Study ID: ATx201-002 (DECOLAD, Part 2)
  • Place: Austria
  • Randomized, double-blind, placebo controlled study
  • 40 atopic dermatitis patients with S. aureus colonization
  • Split body design
  • 7-day treatment, dose optimization
  • Safety and efficacy
  • Microbiological endpoints: Reduced colonization of S. aureus

For more information about this study please visit clinicaltrialsregister.eu and clinicaltrials.gov

 

Phase II - PoC Study in Atopic Dermatitis (30 Patients)

  • Study ID: ATx201-003
  • Place: Canada
  • Randomized, double-blind, placebo controlled study
  • 30 atopic dermatitis patients
  • Safety and efficacy
  • Once daily
  • 21-days treatment
  • 2% and placebo

For more information about this study please visit clinicaltrialsregister.gov

 

Phase II – Impetigo Study (210 Patients) 

  • Study ID: ATx201-004 (Impetigo)
  • Place: South Africa
  • 210 patients with impetigo
  • Randomized, double-blind, vehicle-controlled study
  • Dose optimization
  • Evaluate safety and efficacy

 

Learn more